Back to top

Analyst Blog

Novo Nordisk (NVO - Analyst Report) has a strong presence in the diabetes care market with one of the broadest diabetes portfolios in the industry.

Recently, Novo Nordisk gained a positive opinion in the EU from the Committee for Medicinal Products for Human Use (CHMP) for the expanded use of Tresiba and Victoza in type II diabetes. This recommendation will help doctors in achieving glycemic targets, especially in cases of concern about hypoglycemia and weight gain.

Victoza is a once-daily human glucagon-like peptide 1 (GLP-1) analogue approved for improving blood sugar (glucose) levels in adult type II diabetes patients. Victoza was launched in the EU in 2009 and is marketed in more than 65 countries worldwide. In 2013, Victoza revenues increased 23% y/y (27% in local currencies) to DKK 11.6 billion. Tresiba is an insulin analogue, approved in the EU (Jan 2013) and Japan (2012) for the treatment of type I and type II diabetes. However, the U.S. approval is yet to come.

Once it is approved by the European Commission, Tresiba can be prescribed in combination with Victoza. In the same way, Victoza can be prescribed in combination with Tresiba. The recommendation from the committee was based on data from four phase III studies, conducted in adults with type II diabetes. Pivotal data came from the BEGIN: VICTOZA ADD-ON 26-week study, which was supported by other studies including DUAL I, DUAL II and LIRA-DETEMIR study.

Novo Nordisk carries a Zacks Rank #3 (Hold). We are pleased with the positive opinion from the committee. We note that several big companies like Eli Lilly and Company (LLY - Analyst Report) have a presence in the diabetes market.

Some better-ranked players include Alexion Pharmaceuticals, Inc. (ALXN - Analyst Report) and Alkermes (ALKS - Analyst Report). Both stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ERBA DIAGNO… ERB 3.80 +7.04%
BANCO DO BR… BDORY 14.74 +5.66%
AIR INDUSTR… AIRI 9.99 +4.15%
EQT MIDSTRE… EQM 98.14 +3.38%
WEATHERFORD… WFT 23.64 +3.10%